Author:
Kaiser Erhard,Pollmann Jan,Skurk Carsten,Müller Martin
Publisher
Springer Berlin Heidelberg
Reference78 articles.
1. Antoniucci D, Valenti R, Migliorini A, Moschi G, Trapani M, Dovellini EV, Santoro GM (2002) Abciximab therapy improves survival in patients with acute myocardial infarction complicated by early cardiogenic shock undergoing coronary artery stent implantation. Am J Cardiol 90(4):353–357
2. Basir MB, Schreiber T, Dixon S, Alaswad K, Patel K, Almany S, O'Neill Md WW (2018) Feasibility of early mechanical circulatory support in acute myocardial infarction complicated by cardiogenic shock: The Detroit cardiogenic shock initiative. Catheter Cardiovasc Interv 91(3):454–461
3. Berwanger O (2010) Acetylcysteine for the Prevention of Contrast-Induced Nephropathy (ACT) Trial: a pragmatic multicenter randomized trial to evaluate the efficacy of acetylcysteine for the prevention of renal outcomes in patients undergoing coronary and vascular angiography, Abstract 21843, Tuesday, November 16, 11:51–12:01. American Heart Association’s Scientific Sessions
4. Blomberg H, Gedeborg R, Berglund L, Karlsten R, Johansson J (2011) Poor chest compression quality with mechanical compressions in simulated cardiopulmonary resuscitation: a randomized, cross-over manikin study. Resuscitation 82(10):1332–1337
5. Chan AW, Chew DP, Bhatt DL, Moliterno DJ, Topol EJ, Ellis SG (2002) Long-term mortality benefit with the combination of stents and abciximab for cardiogenic shock complicating acute myocardial infarction. Am J Cardiol 89(2):132–136